Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (8 quarters reported)
$222M in Q4 2021 → $44.5M now. Hover for any quarter.
As reported for the quarter ended September 30, 2023. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Centessa Pharmaceuticals PLC | 42.7% | Unchanged | 2,937,615 | $19M |
| AT Aerovate Therapeutics Inc. | 18.4% | Unchanged | 603,762 | $8.19M |
| Cyteir Therapeutics, Inc. | 15.7% | Unchanged | 2,459,572 | $6.99M |
| Pmv Pharmaceuticals, Inc. | 13.7% | Unchanged | 989,232 | $6.07M |
| GB Graphite Bio | 2.3% | Unchanged | 406,308 | $1.01M |
| SB Selecta Biosciences, Inc. | 2.1% | Unchanged | 862,543 | $914K |
| Vor Biopharma Inc. | 1.8% | Unchanged | 374,714 | $794K |
| ET Effector Therapeutics, Inc. | 1.4% | Unchanged | 1,025,697 | $615K |
| Precision Biosciences, Inc. | 0.9% | Unchanged | 1,123,913 | $384K |
| Spero Therapeutics, Inc. | 0.7% | Unchanged | 249,070 | $301K |
| IO Ikena Oncology, Inc. | 0.3% | New | 26,833 | $116K |
| HM Homology Medicines, Inc. | 0.2% | Unchanged | 64,000 | $74.9K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.
quarter ended September 30, 2023 · filed November 09, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| DT Dice Therapeutics Inc. | Exited | −268,346 | −$12.5M | — |
| IO Ikena Oncology, Inc. | New | +26,833 | +$116K | 0.3% |
quarter ended June 30, 2023 · filed August 07, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ionq, Inc. | Exited | −389,668 | −$2.4M | — |
| Prime Medicine, Inc. | Exited | −121,255 | −$1.49M | — |
quarter ended March 31, 2023 · filed April 24, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ionq, Inc. | Trimmed | −787,929 | −$4.85M | 4.8% |
quarter ended December 31, 2022 · filed February 02, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| DT Dice Therapeutics Inc. | Trimmed | −268,347 | −$8.37M | 13.7% |
| Prime Medicine, Inc. | New | +121,255 | +$2.25M | 3.7% |
| Evolv Technologies Holdings, Inc. | Exited | −652,475 | −$1.38M | — |
| Landos Biopharma, Inc. | Exited | −1,237,667 | −$804K | — |
| Cyteir Therapeutics, Inc. | Trimmed | −10,000 | −$16.5K | 6.6% |
quarter ended September 30, 2022 · filed November 01, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Evolv Technologies Holdings, Inc. | Trimmed | −930,246 | −$1.97M | 2.2% |
| Ionq, Inc. | Trimmed | −200,000 | −$1.01M | 9.3% |
| Landos Biopharma, Inc. | Trimmed | −375,097 | −$244K | 1.3% |
| Cyteir Therapeutics, Inc. | Trimmed | −5,000 | −$9.6K | 7.4% |
quarter ended June 30, 2022 · filed July 19, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ionq, Inc. | Trimmed | −941,922 | −$4.13M | 8.3% |
| Sera Prognostics, Inc. | Exited | −337,505 | −$1.28M | — |
| Evolv Technologies Holdings, Inc. | Trimmed | −238,145 | −$633K | 5.8% |
| Landos Biopharma, Inc. | Trimmed | −214,714 | −$156K | 1.6% |
quarter ended March 31, 2022 · filed May 04, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ionq, Inc. | Trimmed | −1,827,562 | −$23.3M | 22.5% |
| Centessa Pharmaceuticals PLC | Added | +595,724 | +$5.34M | 20.1% |
| Sera Prognostics, Inc. | Trimmed | −303,856 | −$1.15M | 1.0% |
Loading...
